Meniere s Disease Treatment Market

Company Headquarters: Maryland, US Founded: 1987 Workforce: ~2,500 Company Working: Novavax, Inc. is a biotechnology company that commercializes and develops vaccines to prevent a wide range of infectious diseases. It designs recombinant nanoparticle vaccine technology that produces a strong immune response against a variety of pathogens. It is partnered with leading biopharma organizations, government agencies, research institutions, and foundations, namely the Coalition for Epidemic Preparedness Innovations (US), the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (US), the Serum Institute of India Pvt. Ltd. (India), SK Bioscience (South Korea), CPL Biological (India), and Takeda Pharmaceuticals (US). It has seven research and manufacturing facilities. It has presence in regions namely North America, Europe, and the Middle East and Africa

Company Headquarters: Florida, US Founded: 1999 Workforce: ~800 Company Working: Ology Bioservices, Inc. is an integrated biopharmaceutical company that develops and manufactures biopharmaceuticals and medical devices. It specializes in cell therapy, gene therapy, viral vectors, antibodies, oncolytic viruses, biopharmaceutical manufacturing, and vaccines. It has collaboration and partnerships with recognized government agencies, namely the Department of Defense and Medical Countermeasures Advanced Development and Manufacturing, which support it in developing biodefense products. Moreover, it has decades of experience in developing, licensing, and manufacturing proteins, therapeutics, and vaccines. It develops products to offer both commercial customers and US governments. Furthermore, it is a wholly owned company of National Resilience, Inc. (US), and assisting Resilience through its services includes regulatory support from preclinical through licensure and cGMP manufacturing up to biosafety level 3 (BSL3).

Company Headquarters: New York, US Founded: 2003 Workforce: ~150 Company Working: Cleveland Biolabs, Inc. is an innovative biopharmaceutical company developing products to address immune system diseases and serious medical needs. It is specialized in offering products such as radiation injury products, immune-oncology, and orphan drugs. It has nine product candidates in its pipeline that have been developing directly through itself or its wholly owned companies, namely Incuron, LLC (US) and Panacela Labs, Inc. (US). It has a proprietary platform, namely the Advanced Immunomodulating Multi-Receptor System (AIMS) platform, which is designed to restore immune homeostasis. Moreover, it has collaboration with government agencies which supports the advanced development and procurement of new medical countermeasures including drugs, vaccines, diagnostics, and medical supplies in order to protect public health from chemical, biological, radiological, and nuclear threats.

Company Headquarters: Lyon, US Founded: 2009 Workforce: ~25 Company Working: Fabentech Biotech is a pharmaceutical company that develops and manufactures polyclonal antibody treatments. Its platform is safe, tested, and fully validated on polyclonal antibody technology for fighting high-priority biological agents that could threaten public health. It has many local, national, and international partners, namely the National Institutes of Health (UK), US Army, World Health Organization, and the European Defense Fund, who are supporting its biodefense product development. This is the only company in Europe that is able to produce biodefense solutions while adhering to the most strict international norms

Company Headquarters: New Jersey, US Founded: 1998 Workforce: ~25 Company Working: Elusys Therapeutics, Inc. is a commercial-stage biopharmaceutical company that develops antibody-based products to treat infectious diseases. It has partnerships with renowned biodefense associations, including the Centers for Disease Control and Prevention (US), the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (US), and the National Institute of Allergy and Infectious Diseases (US). It supplies its anthrax antitoxin products from the Strategic National Stockpile (US). Moreover, it is a wholly owned subsidiary of NightHawk Biosciences (US) and is expanding NightHawk's biodefense space while also complementing NightHawk’s RapidVax platform, which is designed to specifically target emerging biological threats

Company Headquarters: New York, US Founded: 1995 Workforce: ~50 Company Working: SIGA Technologies (SIGA) is a pharmaceutical business at the commercialization stage that develops and offers antiviral treatments for smallpox, monkeypox, cowpox, and vaccinia complications. The company has an established research and development collaboration with US federal entities. It provides countermeasures to the Strategic National Stockpile (SNS) and the Department of Defense (DoD). TPOXX ("oral TPOXX," also known as "tecovirimat" in certain overseas markets) is the Company's lead product, which it distributes to the US government and international governments (including government-affiliated entities). In addition, the Company sells TPOXX intravenous formulation ("IV TPOXX") to the US Government